Patients and Caregivers

Looking for information on our trials?

Research and Clinical Trials

AGTC is currently conducting clinical studies for the treatment of several genetic blinding diseases. We will update this page on an ongoing basis as new clinical studies begin.

If you have additonal questions about any of our studies, please contact us at advocacy@agtc.com

X-linked Retinoschisis (XLRS)

AGTC is currently conducting a clinical study to evaluate the safety and efficacy of an investigational gene therapy in patients with XLRS.

This study is currently recruiting.

For more information, and to see whether you or someone you know qualifies to join the study, please click here to view the study page on ClinicalTrials.gov.  

Achromatopsia (ACHM B3)

AGTC is currently conducting a clinical study to evaluate the safety and efficacy of an investigational gene therapy in patients with ACHM caused by mutations in the CNGB3 gene (also known as ACHM B3).

This study is currently recruiting.

For more information, and to see whether you or someone you know qualifies to join the study, please click here to view the study page on ClinicalTrials.gov.

Achromatopsia (ACHM A3)

AGTC is planning to begin a clinical study in early 2017 to evaluate the safety and efficacy of an investigational gene therapy in patients with achromatopsia caused by mutations in the CNGA3 gene (also known as ACHM A3).

For more information, and to see whether you or someone you know qualifies to join the study, please click here to view the study page on ClinicalTrials.gov. 

Advocacy & Education

Patients and caregivers interested in learning more about rare and blinding diseases may find valuable information and resources on the following websites:

Patients and Caregivers

Contact Us

Alachua – Headquarters
14193 NW 119th Terrace, Suite #10
Alachua, Florida 32615
386.462.2204
Map
Cambridge
One Kendall Square, 1400W, Suite B14305
Cambridge, MA 02139
617.843.5728
Map

Please enter the letters from the image below in order to prevent spam.